NCT04014101 2019-07-11
SHR-1210
Shanghai Zhongshan Hospital
Phase 2 Unknown
Clinical Trials
6 trialsNCT03775707 2019-05-06
Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria
Sun Yat-sen University
Phase 2 Withdrawn
NCT03803254 2019-05-06
HAIC Plus Lenvatinib and PD-1 Antibody Versus HAIC Plus Lenvatinib for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03782831 2019-05-02
TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03746249 2019-04-17
Phase II of Lenvatinib Plus PD-1 Antibody for Advanced HCC
Sun Yat-sen University
Phase 2 Withdrawn
NCT03857815 2019-03-19
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma
Shanghai Zhongshan Hospital
Phase 2 Unknown